PriceTargets.com logo

Vascular Biogenics - VBLT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.46 As of 10/17/2023 12:59 AM ET
▼ -0.525 (-8.77%)
Get New Vascular Biogenics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VBLT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VBLT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Vascular Biogenics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.46.

This chart shows the closing price for VBLT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Vascular Biogenics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/20/2022Chardan CapitalDowngradeBuy ➝ NeutralLow
7/20/2022HC WainwrightDowngradeBuy ➝ NeutralLow
7/20/2022OppenheimerDowngradeOutperform ➝ Market PerformLow
7/18/2022OppenheimerReiterated RatingOutperform$5.50Low
5/20/2022JonestradingReiterated RatingBuy$5.00High
4/28/2022Chardan CapitalInitiated CoverageBuy$5.00High
11/16/2021HC WainwrightReiterated RatingBuy$4.00Low
6/3/2021Chardan CapitalReiterated RatingBuy$5.00High
6/3/2021Roth CapitalBoost TargetBuy$5.00 ➝ $7.00High
5/18/2021GuggenheimInitiated CoverageBuy$7.00High
1/28/2021HC WainwrightBoost TargetReduce ➝ Buy$3.00 ➝ $4.00Medium
12/10/2020Chardan CapitalReiterated RatingBuyLow
8/13/2020Chardan CapitalReiterated RatingBuy$5.00Low
6/23/2020HC WainwrightReiterated RatingBuy$3.00Low
5/27/2020Roth CapitalReiterated RatingBuy$5.00High
5/14/2020OppenheimerReiterated RatingBuy$2.50High
4/17/2020OppenheimerBoost TargetOutperform$2.00 ➝ $3.00Low
4/5/2020HC WainwrightReiterated RatingBuy$3.00High
4/3/2020Chardan CapitalReiterated RatingBuy$5.00High
3/26/2020Chardan CapitalReiterated RatingBuy$3.25High
3/20/2020HC WainwrightReiterated RatingBuy$3.00Low
3/19/2020Chardan CapitalReiterated RatingBuy$3.25Low
1/10/2020Chardan CapitalReiterated RatingBuy$3.25High
1/2/2020Roth CapitalReiterated RatingBuyLow
11/25/2019Roth CapitalReiterated RatingBuyLow
11/15/2019HC WainwrightReiterated RatingBuy$3.00High
11/14/2019Chardan CapitalUpgradeNeutral ➝ Buy$3.25High
8/13/2019Chardan CapitalReiterated RatingHold$3.00High
6/27/2019CIBCInitiated CoverageOutperform ➝ OutperformHigh
6/27/2019OppenheimerInitiated CoverageOutperform$2.00High
5/16/2019HC WainwrightReiterated RatingBuy$3.00High
5/16/2019Chardan CapitalReiterated RatingHold$3.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Vascular Biogenics logo
Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
Read More

Today's Range

Now: $5.46
Low: $5.34
High: $6.74

50 Day Range

MA: $0.40
Low: $0.16
High: $5.46

52 Week Range

Now: $5.46
Low: $0.10
High: $6.74

Volume

161,505 shs

Average Volume

2,187,886 shs

Market Capitalization

$423.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Vascular Biogenics?

The following Wall Street analysts have issued research reports on Vascular Biogenics in the last year: StockNews.com.
View the latest analyst ratings for VBLT.

What is the current price target for Vascular Biogenics?

0 Wall Street analysts have set twelve-month price targets for Vascular Biogenics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Vascular Biogenics in the next year.
View the latest price targets for VBLT.

What is the current consensus analyst rating for Vascular Biogenics?

Vascular Biogenics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VBLT.

What other companies compete with Vascular Biogenics?

Other companies that are similar to Vascular Biogenics include Avid Bioservices, Lexicon Pharmaceuticals, Entrada Therapeutics, Larimar Therapeutics and ADC Therapeutics. Learn More about companies similar to Vascular Biogenics.

How do I contact Vascular Biogenics' investor relations team?

Vascular Biogenics' physical mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company's listed phone number is (728) 993-5000 and its investor relations email address is [email protected]. The official website for Vascular Biogenics is www.vblrx.com. Learn More about contacing Vascular Biogenics investor relations.